Bør flere tilbys behandling med cannabinoider? | Tidsskrift for Den norske legeforening Bør flere tilbys behandling med cannabinoider? KRONIKK INGRID ANNA TEIGEN E-post: ingrid.anna.teigen@helse-bergen.no Ingrid Anna Teigen er lege i spesialisering ved Seksjon for klinisk farmakologi, Avdeling for medisinsk biokjemi og farmakologi, Haukeland universitetssjukehus. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. TROND TRAETTEBERG SERKLAND Trond Traetteberg Serkland er lege i spesialisering ved Seksjon for klinisk farmakologi, Avdeling for medisinsk biokjemi og farmakologi, Haukeland universitetssjukehus. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. THOMAS PAHR Thomas Pahr er konstituert overlege ved Avdeling Østmarka, Divisjon psykisk helsevern, St. Olavs hospital. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
JON ANDSNES BERGJon Andsnes Berg er overlege ved Seksjon for klinisk farmakologi, Avdeling for medisinsk biokjemi og farmakologi, Haukeland universitetssjukehus. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant that has gained popularity as an illicit recreational drug. We describe a case of an elderly woman who was found unconscious in her home. The paramedics initially suspected an intracranial incident. A head computed tomography (CT) was negative, as was the initial urinary drug screening. The diagnosis of GHB intoxication was made with detection of GHB in a urine sample obtained 28-29 hours after assumed time of intake. Our case underscores the importance of considering drug testing in a broad range of patients, and shows that elderly patients may have an extended detection window of GHB.
who helped to collect specimens; and Wesley Cheng, BS, for help with REDCap. All received salary support from the study and are staff at Children's Hospital Los Angeles. 1. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. Accessed February 23, 2021. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinicalspecimens.html 2. Moreno-Contreras J, Espinoza MA, Sandoval-Jaime C, et al. Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 diagnostic tests in settings with supply shortages.
The aim of this pilot study was to investigate whether psychotropic drugs frequently analyzed in a routine therapeutic drug monitoring (TDM) laboratory bind to low density lipoproteins/very low-density lipoproteins (LDL/VLDL) in human serum.
METHODS:Drug concentrations in 20 serum sample pools containing one psychotropic drug each, and in the LDL/VLDL fractions extracted from the same samples, were measured by triple quadrupole liquid chromatography tandem mass spectrometry (LC-MS/MS). The membrane permeability of the drugs was measured using a Parallel Artificial Membrane Permeability Assay (PAMPA).
RESULTS:Out of the 20 antidepressants, antipsychotics and antiepileptics examined, seven drugs were detected in both the pooled serum samples and in the LDL/VLDL fraction.Binding of drugs to LDL/VLDL significantly correlated with high octanol:water partition coefficient (logP), high degree of protein binding (PB) and a low polar surface area (PSA).The drugs found in LDL/VLDL, with the exception of aripiprazole, were also characterized by high or intermediate membrane permeability.
CONCLUSIONS:The present results indicate that psychotropic drugs with certain characteristics bind to LDL/VLDL in blood. This further implies that lipoproteins could play an important role in drug transport.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.